Because TDP-43 misfolding causes loss of function, as well as providing a substrate for aggregation and gain-of-function/dominant-negative toxicity, we see early misfolding events as one of the most attractive therapeutic targets in ALS with TDP-43 proteinopathy. The gene discussed is TARDBP; the disease is proteostasis deficiencies.